11. P423 Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies. (27th May 2021) Authors: Picker, N; Patel, H; Wilke, T; Rosin, L; Bokemeyer, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. P464 Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-setting. (27th May 2021) Authors: Bokemeyer, B; Picker, N; Wilke, T; Rosin, L; Patel, H Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S455 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. P468 Analysis of international spontaneous reporting system databases for safety of corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and consequences of Corticosteroid Excess (DICE)-impact study. (27th May 2021) Authors: Raine, T; Bokemeyer, B; Finney-Hayward, T; Munsaka, M; Liu, M; Louis, E Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. P478 Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemia. (16th January 2018) Authors: Schmidt, C; Baumgart, D; Bokemeyer, B; Büning, C; Howaldt, S; Stallmach, A; Singfield, C; Tremblay, G; Jones, T Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S346 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. P506 Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany. (21st January 2022) Authors: Bokemeyer, B; Picker, N; Kromer, D; Rosin, L; Patel, H Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab. (25th January 2019) Authors: Bokemeyer, B; Hlavaty, T; Allez, M; Selema, P; Moosavi, S; Cadatal, M J; Fowler, H; Cheung, R; Lukas, M; Gisbert, J P Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. P598 Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice. (21st January 2022) Authors: Bokemeyer, B; Picker, N; Kromer, D; Rosin, L; Patel, H Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i532 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. P601 Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study. (21st January 2022) Authors: Bokemeyer, B; Plachta-Danielzik, S; di Giuseppe, R; Deppe, H; Mohl, W; Teich, N; Hoffstadt, M; Schweitzer, A; von der Ohe, M; Gauss, A; Atrya, R; Krause, T; Blumenstein, I; Höchstödter, J; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. P635 Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1, 149 patients treated in Germany. (16th January 2018) Authors: Groth, A; Wilke, T; Brandes, A; Ratsch, B; Fuchs, A; Deiters, B; Bokemeyer, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S431 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics. (15th January 2020) Authors: Bokemeyer, B; Plachta-Danielzik, S; Sobotzki, C; Mohl, W; Hoffstadt, M; Krause, T; Atreya, R; von der Ohe, M; Graefe, U; Trentmann, L; Eisold, M; Linde, A; Franzenburg, S; Moser, M; Hartmann, P; Schreiber, S Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S584 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗